NEW YORK, Dec 6 (Reuters) - Johnson & Johnson said on Wednesday it suspended enrollment in a late-stage trial of an experimental rheumatoid arthritis drug it is co-developing with Schering-Plough Corp. (SGP.N: Quote, Profile , Research) because of short-term logistics problems.
